Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rituximab + gemcitabine + ifosfamide + oxaliplatin (R-GIFOX) in relapsed or refractory aggressive CD20-positive lymphoma
2006-003243-23Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, gemcitabine, ifosfamide and oxaliplatin in B-cell non-Hodgkin lymphoma (B-NHL) and classical Hodgkin lymphoma (cHL), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Overall Early Response Rate. Started Jun 2007; status: active.
02
Drugs
rituximabgemcitabineifosfamideoxaliplatin
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2006-003243-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003243-23.